


Product Information

– for professionals only –



Serin⁵⁰⁰ minis



In Short

- Serin⁵⁰⁰ minis are a Food for Special Medical Purposes (FSMP) for use in the dietary management of rare metabolic disorders, e.g. GRIN2B-associated Encephalopathy or Serine Deficiency Disorders, when supplementation with L-Serine is indicated
- highly concentrated, pressed and coated L-Serine – in tablet form
- easy to swallow – easy application
- neutral in smell and taste
- 500 mg (4,8 mmol) L-Serine per tablet – 158 g tin at 250 tablets

References:

- 1) van der Crabben, SN et al. (2013) An update on serine deficiency disorders. J Inher Metab Dis 36:613–619. doi.org/10.1007/s10545-013-9592-4.
- 2) van Konijnenburg et al. (2021) Treatable inherited metabolic disorders causing intellectual disability: 2021 review and digital app; Orphanet Journal of Rare Diseases 16(1):170. doi: 10.1186/s13023-021-01727-2.

Product Profile

Serin⁵⁰⁰ minis are highly concentrated L-Serine in tablet form – pressed and coated.

Serin⁵⁰⁰ minis allow a tasteless intake of this L-amino acid.

Due to their dosage form they offer a convenient alternative, flexible and easy to take and simple to measure out.

Serin⁵⁰⁰ minis are not fortified with micronutrients.

Indication Serin is used for the dietary management of rare metabolic disorders, when supplementation with L-Serine is indicated. These include Serine Deficiency Disorders (1), e.g.

- 3-phosphoglycerate dehydrogenase deficiency
- L-serine biosynthesis phosphoserine aminotransferase deficiency (rare)
- phosphoserine phosphatase deficiency (very rare).

The review by Hoytema van Konijnenburg (2) also mentions the mitochondrial aspartate aminotransferase deficiency and seryl-tRNA synthetase 1 deficiency as indications. Likewise, L-serine is used for the dietary management of GRIN2B-associated Encephalopathy, a congenital neurotransmitter disorder caused by NMDA receptor deficiency (ionotropic glutamate receptor NMDA type subunit 2B dysregulation).

Dosage The daily dosage depends on age, body weight and individual medical condition and is, just as the right time for the daily intake, determined under medical supervision.

Important Notice Only to be taken under strict medical supervision. Not suitable as sole source of nutrition. For enteral use only. Only for people with rare metabolic disorders, e.g. GRIN2B-associated Encephalopathy or Serine Deficiency Disorders. Serin⁵⁰⁰ minis are not suitable for infants in the first year of life.

Administration

Serin⁵⁰⁰ minis should always be taken with a sufficient quantity of liquid and at best along with other food.

Intake

The tablets should be swallowed unchewed as whole tablets. They should always be taken with a sufficient quantity of liquid. The tablets are not intended to be dissolved in water or other drinks prior to intake and they are not meant to dissolve in the mouth. We recommend to take the tablets in an upright position. The box must be closed tightly after use, also with the inner lid.

Note: The tablets are covered with a tasteless coating. This makes it easy to swallow them. However the layer is very thin. Thus, if the tablets were kept in the mouth for too long, this layer would dissolve and release the typical taste of an amino acid. This is why we recommend the administration above.

□—————□
Function Serin⁵⁰⁰ minis are suitable for prevention or correction of disease related L-Serine deficiencies.

NUTRITION INFORMATIONSerin⁵⁰⁰ minis

100 g

0,63 g
(1 tablet)

Energy	kJ	1300	8
		kcal	308
Fat	g	1	<0,1
		of which saturates	<0,1
Carbohydrate	g	0	0
		of which sugars	0
Fibre	g	17	0,1
Protein eqv.	g	67	0,4
		of which L-Serine	0,5
	mmol		4,8
Salt	g	0	0

INGREDIENTS

L-serine, bulking agents: microcrystalline cellulose & silicon dioxide, anti-caking agents: calcium silicate & magnesium stearate & magnesium carbonate & calcium phosphate, glazing agents: E 464 & E 463.

Delivery Unit	tin 250 tablets = 158 g
Article Number	xx-001-31806
Delivery to	Pharmacies, clinics
Storage	Store in a cool, dry place.